Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON42553
NL-OMON42553CompletedPhase 2

A randomized, placebo-controlled, 2-way crossover, double-blind study to evaluate the efficacy, safety and tolerability of JNJ-42847922 in subjects with insomnia disorder without psychiatric comorbidity. - JNJ-42847922 for insomnia without psychiatric comorbidity.

Janssen-Cilag0 sites8 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
8
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •Healthy male and female participants aged between 18 and 65 years, inclusive
  • •- Body mass index (BMI) between 18 and 30 kilogram per square meters (kg/m^2) inclusive (BMI = weight/height^2)
  • •- Insomnia Severity Index (ISI) score more than or equal to 15 at screening
  • •- Insomnia: at screening participants will report both difficulties with sleep onset and sleep maintenance. Insomnia will furthermore objectively be established prior to enrollment per PSG recorded over 3 consecutive nights. Participants will sleep for 3 consecutive nights in the sleep center. First and second night data will be used to exclude any participant with restless leg syndrome, apnea, parasomnias or other sleepdisorders. On the second and third night participants are required to meet objective inclusion criteria: 2-night mean LPS of >= 30 minutes with no night < 20 minutes, and on both nights TST =< 6 hours and wake after sleep onset (WASO) >30 minutes
  • •- Participants must be healthy /medically stable on the basis of clinical laboratory tests, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and baseline

Exclusion Criteria

  • •Participant has current signs/symptoms of, liver or renal insufficiency; hypothyroidism or hyperthyroidism, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disturbances. Participants with non-insulin dependent diabetes mellitus who are adequately controlled (not on insulin) may participate in the study
  • •- History of epilepsy or fits or unexplained black-outs
  • •- Clinically significant abnormal values for hematology, clinical chemistry or urinalysis at screening or admission
  • •- Clinically significant abnormal physical and neurological examination, vital signs or 12-lead ECG at screening or baseline
  • •- Smoking >10 cigarettes/daily
  • •- Insomnia related to restless leg syndrome, sleep breathing disorder, narcolepsy, obstructive sleep apnea/hypopnea, central sleep apnea, sleep-related hypoventilation, circadian rhythm sleep-wake disorders, substance/medication-induced sleep disorder or parasomnias
  • •- Night-shift worker or significantly shifted diurnal activity pattern

Investigators

Similar Trials

Active, not recruiting
Phase 1
A randomized, placebo-controlled, 2-way crossover, double-blind study to evaluate the efficacy, safety and tolerability of JNJ-42847922 in subjects with insomnia disorder without psychiatric disease.Insomnia
EUCTR2015-001672-22-DEJanssen-Cilag International NV26
Active, not recruiting
Not Applicable
A randomized, placebo-controlled, 2-way crossover, double-blind study to evaluate the efficacy, safety and tolerability of JNJ-42847922 in subjects with insomnia disorder without psychiatric disease.Insomnia
EUCTR2015-001672-22-NLJanssen-Cilag International NV26
Active, not recruiting
Not Applicable
The Influence of Ivabradine on the Symptoms of Neuropathic Pain (IISNeP)europathic PainMedDRA version: 14.0Level: PTClassification code 10029223Term: NeuralgiaSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2011-003933-32-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge12
Active, not recruiting
Phase 1
A study to learn how safe BAY 2395840 is and how well it works in participants who have diabetic nerve pain.europathic pain associated with diabetic peripheral neuropathyMedDRA version: 21.1Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painSystem Organ Class: 100000004852
EUCTR2021-001392-17-ESBayer AG80
Active, not recruiting
Phase 1
A study to learn how safe BAY 2395840 is and how well it works in participants who have diabetic nerve paieuropathic pain associated with diabetic peripheral neuropathyMedDRA version: 21.1Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painSystem Organ Class: 100000004852
EUCTR2021-001392-17-SKBayer AG75